-

Thermo Fisher Scientific Launches New ENERGY STAR certified TSX Universal Series ULT Freezers to Deliver Tighter Temperature Control and Faster Recovery Times

Enhanced performance and 33% energy savings support quality and sustainability goals in the laboratory

CARLSBAD, Calif.--(BUSINESS WIRE)--Building on 80 years of expertise engineering cold storage lab equipment, Thermo Fisher Scientific today introduces its newest line of high performance, ultra-low temperature (ULT) freezers. With enhancements to performance, user experience and energy efficiency, the Thermo Scientific™ TSX™ Universal Series ULT Freezers seamlessly adapt to scientists’ workflows across a variety of lab settings, marking a new era in performance, reliability, and sustainability.

Laboratories require reliable and effective cold storage solutions for their samples, often at a very specific temperature range, to advance critical research, adequately store samples or accelerate the development of new therapies. With Universal V-Drive technology, tighter control, faster recovery times, universal voltage, and an expanded setpoint range, the TSX Universal Series seamlessly adapts to diverse workflows, from high-use academic labs to longer-term storage facilities. Delivering both industry leading performance and energy efficiency, the TSX Universal Series allows labs to meet their sustainability goals without sacrificing performance.

“With the advancement of new therapeutic technologies and tighter regulatory focus on the pharmaceutical cold chain, there’s a clear need for enhanced and manageable cold storage solutions across a variety of settings,” said Carlos Sevilla, vice president and general manager, Controlled Temperature Technologies at Thermo Fisher Scientific. “Following extensive research and development, we’re proud to launch the next generation TSX Universal Series of ULTs, enabling high-use academic labs, GMP labs and long-term storage facilities to use the same unit throughout diverse workflows while supporting their own sustainability goals.”

TSX Universal Series ULT freezers undergo rigorous long-term reliability testing, having undergone +5400 combined days of continuous reliability testing in the field and laboratory environments to help ensure each unit meets Thermo Fisher Scientific's stringent quality standards. ENERGY STAR® certified and produced in a Zero-Waste to Landfill certified facility, the TSX Universal Series ULT freezers are designed with sustainability in mind and provide easy-to-use information about the products' environmental impact through the ACT label program, run by the non-profit organization My Green Lab.

For the first time, the TSX Series ULT platform offers medical device units, to store and preserve blood and blood products at freezing temperatures between -40°C to -86°C for users operating in GMP or qualified environments.* By obtaining ISO Class 5.5 cleanroom designation for TSX Universal Series ULT freezers, cell and gene therapy customers can have confidence in the cleanliness and control of their storage environments. Additionally, customers can benefit from an industry-leading warranty and global service support through Unity Lab Services.

To learn more about the new TSX Universal Series ULTs, please visit www.thermofisher.com/TSXUniversalULT

*Registered as a medical device in the US only. Verification of medical devices in the U.S. can be found on: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfrl/rl.cfm

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media Contact Information:
Shannon Stoneking
Phone: 484-748-1279
E-mail: shannon.stoneking@thermofisher.com

Jessika Parry
Phone: 419-266-4016
Email: jparry@greenoughagency.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Versions

Contacts

Media Contact Information:
Shannon Stoneking
Phone: 484-748-1279
E-mail: shannon.stoneking@thermofisher.com

Jessika Parry
Phone: 419-266-4016
Email: jparry@greenoughagency.com

More News From Thermo Fisher

Thermo Fisher Scientific Deepens Investment in Asia’s Biopharma Ecosystem with Expansion of Bioprocess Design Centers

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced an expansion of its bioprocessing capabilities across Asia, reinforcing its commitment to supporting the region’s rapidly growing biopharmaceutical industry. The company is introducing a new Bioprocess Design Center in Hyderabad, India, and has expanded its existing Bioprocess Design Centers in Incheon, Korea and Singapore, further strengthening a strategic regional network desig...

Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of €2.1 billion aggregate principal amount (the “Offering”) of the following euro-denominated notes, which will be issued by Thermo Fisher Scientific (Finance I) B.V., its indirect, wholly-owned finance subsidiary: €1,000,000,000 aggregate principal amount of its floating rate senior notes due 2027 (the “floating rate notes”) at the issue price of 100.000%...

Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic (CDx) to identify patients who may be eligible for treatment with HYRNUO™ (sevabertinib), a new HER2-directed therapy developed and commercialized by Bayer. The test enables clinicians and pathologists to identify non-small cell lung cancer (NSCLC) tumors wi...
Back to Newsroom